's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » Hot Stocks Free for All ! » This is a mortal lock IMO- CGCP

 - UBBFriend: Email this page to someone!    
Author Topic: This is a mortal lock IMO- CGCP

Member Rated:
Icon 1 posted      Profile for ohio_trader         Edit/Delete Post   Reply With Quote 
To all longs is a gimme to all members who can afford to go long 1-2 years to make 500-5000% on your $$$

symbol: CGCP
price .51 as of 3/7/2006


I live in NE Ohio..were the best heart hospitals in the world (bar none) are located....the Cleveland Clinic( does procedures routinely for Arab sheiks, amd million and billionaires that come from all over the world ), Akron City Hospital( who performs a procedure by laser that was created by Cardiogenesis) it was in the local paper last week...The Akron Beacon Journal(can be found under
Only 4 hospitals in the country are currently doing this fairly simple procedure( again laser no cuts, for some instant relief, no scarring, infections, rejections on the heart). Within a few years it will be performed in every reputable hosptal that does heart surgery around the world.

****This stock could easily be a $5.00- 20.00 play in 1-2 years, but damn near certain IMO to make $1.00-2.00 range***

Press Release Source: Cardiogenesis Corporation

Cardiogenesis Announces Publication on Holmium:YAG TMR System in Prominent Scientific Journal
Tuesday March 7, 7:30 am ET
Article Highlights Company's Advanced Minimally Invasive System, Potential When Combined with Biologic/Pharmacologic Agents

FOOTHILL RANCH, Calif., March 7 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, announced today the publication of an Expert Review of Medical Devices focused on the Company's Holmium:YAG TMR system in the March edition of Future Drugs.

Future Drugs is a scientific publication based in the UK that provides healthcare practitioners and research professionals with objective cutting-edge information on exciting emerging trends in healthcare and advances in the major therapeutic areas through the Expert Review series.

Chairman and CEO, Michael J. Quinn commented on this prominent publication. "It is noteworthy to see recognition of the increasing clinical importance of the TMR therapy in a cutting edge scientific journal. This is a reflection of the substantial published body of evidence supporting the clinical significance of our Holmium:YAG TMR system, and our efforts in advancing the technology to improve patient outcomes. We are now completing the IDE feasibility trials with our minimally invasive PEARL surgical delivery systems, and have initiated our preliminary safety and feasibility trial with our advanced PHOENIX Revascularization Delivery System for the precise targeted delivery of biologic or pharmacologic materials to the Holmium:YAG thermoacoustic stimulated tissue zone surrounding our TMR channels."

The Expert Review article "Holmium:YAG laser system for transmyocardial revascularization" is authored by Keith B. Allen, MD of the Heart Center of Indiana. In his discussion of mechanism of action, the author highlights the more than 20 peer reviewed works published from researchers at Duke University Medical Center. He states, "Angiogenesis is the most likely mechanism of action responsible for clinical improvement following TMR, and research should be continued to find ways to augment this process."

Mr. Quinn stated, "We are taking the important next steps with TMR to increase its physiologic and clinical impact. Reducing the surgical injury required in delivering this powerful therapy with our minimally invasive PEARL Robotic and Thoracoscopic delivery systems is an important platform improvement. We are now leveraging our understanding of the thermoacoustic stimulated tissue zone created by our Holmium:YAG fiberoptic delivery system for the delivery of potent therapeutic agents to generate an even greater response. The PHOENIX combination delivery system provides the precise and targeted delivery of biologic or pharmacologic therapeutic agents directly into and around the thermoacoustic stimulated tissue zone."

In the Future Drugs article, the author cited the improved Kaplan Meier survival at 5 years achieved with the Cardiogenesis Holmium:YAG system (Annals of Thoracic Surgery. 78, 458-65 (2004)). Dr. Allen stated in his remarks, "Considering the increased operative and long term cardiac risks predicted by incomplete revascularization and the documented operative and long term benefits associated with adjunctive TMR in randomized patients with diffuse CAD, increased utilization of this therapy is warranted. In parallel, it is imperative that research continues into identifying growth factor, therapeutic or stem cell-based materials, which when coadministered may enhance these positive outcomes."

Mr. Quinn concluded, "We strongly agree with Dr. Allen's conclusion that the published results of TMR as a primary and secondary therapy supports increased utilization of TMR in the treatment of diffuse coronary artery disease. We are also focused on advancing the technology to make available our minimally invasive PEARL delivery systems and the PHOENIX combination delivery system to optimize patient outcomes."

About Cardiogenesis Corporation

Cardiogenesis is a medical device Company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.

For more information on the Company and its products, please visit the Cardiogenesis company web site at or the patient and physician website at is a resource for patients and physicians which provides medical information on TMR.

****This is Ohio_Traders gimme to all...kinda inside via heart surgeons I know and local knowledge via the paper*****

*** do your homework ***

Ohio_ Trader

Posts: 1551 | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator

Member Rated:
Icon 1 posted      Profile for ohio_trader         Edit/Delete Post   Reply With Quote 

Jim Steele went to Akron City Hospital seeking a cure for his major heartache. He left with a hole in his heart -- 24 holes, to be precise. The 73-year-old Green resident recently became one of the first patients to undergo a new minimally invasive version of a surgery that uses a laser to poke tiny, pinpoint-sized channels in the heart muscle. The result is relief from the unbearable pain of severe angina. The procedure, called transmyocardial revascularization or TMR, has been

Published on February 27, 2006, Page A1, Akron Beacon Journal OH

you have to subscribe to for the complete article

***this stock is for real, no b.s.***

**do your homework**


Posts: 1551 | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator

Member Rated:
Icon 1 posted      Profile for ohio_trader         Edit/Delete Post   Reply With Quote 
Did anyone check this out ?
Posts: 1551 | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins

Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2019 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2